Fenwick Represents DICE Therapeutics in $204 Million Initial Public Offering

By: Matthew Rossiter, Robert A. Freedman, Amanda L. Rose, Michael M. Shaw, Myles Gutenkunst, Frances Fuqua, Riddhi Adhikari, Marshall Mort, Christophe Delrieu, Jonathan Stephenson, William R. Skinner

Fenwick represented DICE Therapeutics (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, in its upsized initial public offering of 12,000,000 shares of its common stock at a public offering price of $17 per share. The gross proceeds from the offering were $204 million.

The shares began trading on the Nasdaq Global Market on September 15, 2021. BofA Securities, SVB Leerink and Evercore ISI acted as joint bookrunning managers for the offering. More information can be obtained from DICE’s announcement.

The Fenwick transaction team includes corporate partners Matthew Rossiter, Robert Freedman and Amanda Rose and associates Michael Shaw, Myles Gutenkunst, David Kryzanovsky, Frances Fuqua and Riddhi Adhikari; executive compensation and employee benefits partner Marshall Mort and associates Christophe Delrieu and Jonathan Stephenson; and tax partner Will Skinner.

Login

Don’t have an account yet?

Register